董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 胡正国 | 男 | Independent Director | 57 | 39.00万美元 | 未持股 | 2020-05-01 |
| Tyrell Rivers | 男 | Independent Director | 47 | 未披露 | 未持股 | 2020-05-01 |
| Zhengbin Yao | 男 | Chairman, President and Chief Executive Officer | 54 | 274.75万美元 | 未持股 | 2020-05-01 |
| Yanling Cao | 男 | Director | 36 | 1.80万美元 | 未持股 | 2020-05-01 |
| Chris Nolet | 男 | Independent Director | 63 | 40.80万美元 | 未持股 | 2020-05-01 |
| Rachelle Jacques | 男 | Independent Director | 49 | 未披露 | 未持股 | 2020-05-01 |
| Andreas Wicki | 男 | Independent Director | 61 | 未披露 | 未持股 | 2020-05-01 |
| Pascal Soriot | 男 | Independent Director | 60 | 未披露 | 未持股 | 2020-05-01 |
| 胡正国 | 男 | Independent Director | 57 | 未披露 | 未持股 | 2020-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zhengbin Yao | 男 | Chairman, President and Chief Executive Officer | 54 | 274.75万美元 | 未持股 | 2020-05-01 |
| Jorn Drappa | 男 | Chief Medical Officer, Head of Research and Development | 55 | 165.11万美元 | 未持股 | 2020-05-01 |
| Aaron Ren | 男 | Vice President, Head of Business Development and Operations | 43 | 57.04万美元 | 未持股 | 2020-05-01 |
| Mitchell Chan | 男 | Chief Financial Officer | 39 | 89.24万美元 | 未持股 | 2020-05-01 |
| William Ragatz | 男 | Vice President, Head of Commercial | 51 | 未披露 | 未持股 | 2020-05-01 |
| Jim Kastenmayer | 男 | Secretary and General Counsel | 48 | 未披露 | 未持股 | 2020-05-01 |
董事简历
中英对照 | 中文 | 英文- 胡正国
-
Edward Hu（胡正国），1962年12月出生，硕士，美国国籍，已取得中华人民共和国外国人永久居留证。现任无锡药明康德新药开发股份有限公司副董事长、全球首席投资官、高端治疗事业部首席执行官。Edward Hu（胡正国）先生于1983年至1985年间，于杭州大学科学仪器厂任工程师；1988年至1989年间，于中国大恒公司任经理；1989年至1990年间，于德国Jurid Bremsbrag GmbH任工程师；1996年至1998年间，于美国默沙东任高级财务分析师；1998年至2000年间，于美国Biogen Inc.任商业策划经理；2000年至2007年间，历任美国Tanox,Inc.财务总监、运营副总裁、高级副总裁及首席运营官；2007年至今，在无锡药明康德新药开发股份有限公司（包括公司的前身）任职，历任常务副总裁及首席运营官、首席财务官、联席首席执行官、副董事长、全球首席投资官、高端治疗事业部首席执行官等职务。Edward Hu（胡正国）先生还同时在CStone Pharmaceuticals（股票代码：2616.HK）、北海康成制药有限公司（股票代码：1228.HK）担任董事职务。过去三年，Edward Hu（胡正国）先生曾在WuXi Biologics（Cayman）Inc.（股票代码：2269.HK）、Viela Bio,Inc（股票代码：VIE.NASDAQ）、Ambrx Biopharma Inc.（股票代码：AMAM.NYSE）担任董事职务。Edward Hu（胡正国）先生于杭州大学（现为浙江大学）获得物理学学士学位，于美国卡耐基梅隆大学获得化学硕士学位和工商管理硕士学位。于2022年07月05日获委任为北海康成制药有限公司薪酬委员会委员。于2021年7月9日获委任为基石药业投资委员会主席、战略委员会委员。
暂无英文简介 - Edward Hu（胡正国），1962年12月出生，硕士，美国国籍，已取得中华人民共和国外国人永久居留证。现任无锡药明康德新药开发股份有限公司副董事长、全球首席投资官、高端治疗事业部首席执行官。Edward Hu（胡正国）先生于1983年至1985年间，于杭州大学科学仪器厂任工程师；1988年至1989年间，于中国大恒公司任经理；1989年至1990年间，于德国Jurid Bremsbrag GmbH任工程师；1996年至1998年间，于美国默沙东任高级财务分析师；1998年至2000年间，于美国Biogen Inc.任商业策划经理；2000年至2007年间，历任美国Tanox,Inc.财务总监、运营副总裁、高级副总裁及首席运营官；2007年至今，在无锡药明康德新药开发股份有限公司（包括公司的前身）任职，历任常务副总裁及首席运营官、首席财务官、联席首席执行官、副董事长、全球首席投资官、高端治疗事业部首席执行官等职务。Edward Hu（胡正国）先生还同时在CStone Pharmaceuticals（股票代码：2616.HK）、北海康成制药有限公司（股票代码：1228.HK）担任董事职务。过去三年，Edward Hu（胡正国）先生曾在WuXi Biologics（Cayman）Inc.（股票代码：2269.HK）、Viela Bio,Inc（股票代码：VIE.NASDAQ）、Ambrx Biopharma Inc.（股票代码：AMAM.NYSE）担任董事职务。Edward Hu（胡正国）先生于杭州大学（现为浙江大学）获得物理学学士学位，于美国卡耐基梅隆大学获得化学硕士学位和工商管理硕士学位。于2022年07月05日获委任为北海康成制药有限公司薪酬委员会委员。于2021年7月9日获委任为基石药业投资委员会主席、战略委员会委员。
- 暂无英文简介
- Tyrell Rivers
-
Tyrell Rivers自2018年2月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司（AstraZeneca&8217；）企业发展集团的执行董事，负责战略股权投资、并购和撤资，自2014年以来一直担任该职位。在担任该职位之前，Rivers博士从2009年到2014年在MedImmune Ventures任职，在那里他专门从事生物技术投资，并从2001年到2007年在默克制药公司工作，在那里他担任各种技术和商业职务，责任越来越大。Rivers博士担任ADC Therapeutics SA、Armaron Bio Ltd、Cerapedics，Inc.和Corvidia Therapeutics，Inc.以及之前的G1治疗公司和PhaseBioPharmaceuticals，Inc.的董事。Rivers博士拥有麻省理工学院（Massachusetts Institute of Technology）的化学工程学士学位，得克萨斯大学奥斯汀分校（University of Texas at Austin）的化学工程博士学位，以及纽约大学斯特恩商学院（New York University Stern School of Business）的工商管理硕士学位。
Tyrell Rivers has served as a member of our board of directors since February 2018. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has held this position since 2014. Prior to this role, Dr. Rivers was at MedImmune Ventures from 2009 until 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he worked in various technical and business roles of increasing responsibility. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Cerapedics, Inc., and Corvidia Therapeutics, Inc. and previously G1 Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Rivers holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business. - Tyrell Rivers自2018年2月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司（AstraZeneca&8217；）企业发展集团的执行董事，负责战略股权投资、并购和撤资，自2014年以来一直担任该职位。在担任该职位之前，Rivers博士从2009年到2014年在MedImmune Ventures任职，在那里他专门从事生物技术投资，并从2001年到2007年在默克制药公司工作，在那里他担任各种技术和商业职务，责任越来越大。Rivers博士担任ADC Therapeutics SA、Armaron Bio Ltd、Cerapedics，Inc.和Corvidia Therapeutics，Inc.以及之前的G1治疗公司和PhaseBioPharmaceuticals，Inc.的董事。Rivers博士拥有麻省理工学院（Massachusetts Institute of Technology）的化学工程学士学位，得克萨斯大学奥斯汀分校（University of Texas at Austin）的化学工程博士学位，以及纽约大学斯特恩商学院（New York University Stern School of Business）的工商管理硕士学位。
- Tyrell Rivers has served as a member of our board of directors since February 2018. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has held this position since 2014. Prior to this role, Dr. Rivers was at MedImmune Ventures from 2009 until 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he worked in various technical and business roles of increasing responsibility. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Cerapedics, Inc., and Corvidia Therapeutics, Inc. and previously G1 Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Rivers holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business.
- Zhengbin Yao
-
Zhengbin Yao自2017年1月以来一直担任我们的董事会成员。姚博士自2018年2月起担任专注于自身免疫性和严重炎症性疾病的临床阶段生物技术公司VielaBio，Inc.的首席执行官，并自2019年1月起担任其董事会主席。2010年10月至2018年2月，姚博士在MedImmune担任多个领导职位，最近担任呼吸，炎症，自身免疫IMED高级副总裁，负责人。姚博士还担任阿斯利康公司免疫肿瘤专营权的高级副总裁，负责人。在MedImmune和AstraZeneca任职之前，姚博士曾担任Genentech免疫学，传染病，神经科学和代谢疾病PTL主管。此前，姚博士是Tanox，Inc.的Vice President和研究主管，该公司于2007年被Genentech收购。姚博士是VielaBio，Inc.和Immune-ONC Therapeutics，Inc.（一家开发癌症生物疗法的私营生物技术公司）的董事。姚博士在中国安徽安徽医科大学获得免疫学硕士学位，并在爱荷华大学获得微生物学和免疫学博士学位。
Zhengbin Yao has served as a member of the Board since June 2021. From May 2021 to the present, Dr. Yao served as the Chief Executive Officer and chairman of the board of directors of ArriVent Biopharma, a biotechnology company. From March 2018 to March 2021, Dr. Yao served as the Chief Executive Officer, President, and from January 2019 to March 2021 also as chairman of the board of directors of Viela Bio, Inc., a biotechnology company, until it was acquired by Horizon Therapeutics in March 2021. From October 2010 to February 2018, Dr. Yao served as Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED at MedImmune, the biologics division of AstraZeneca plc and from October 2015 to February 2018 also as Senior Vice President, Head of Immuno Oncology Franchise. From March 2008 to September 2010, Dr. Yao served as Head of PTL for Immunology, Infectio Diseases, Neuroscience, and Metabolic Disease at Genentech, Inc., a biopharmaceutical company. From October 2000 to September 2007, Dr. Yao held vario leadership roles at Tanox Inc., a biopharmaceutical company, and was Vice President and Head of Research before it was acquired by Genentech, Inc. in 2007. Dr. Yao currently serves on the board of directors of Visen Pharmaceuticals, a biopharmaceutical company, and Nikang Therapeutics, Inc., a biotechnology company. - Zhengbin Yao自2017年1月以来一直担任我们的董事会成员。姚博士自2018年2月起担任专注于自身免疫性和严重炎症性疾病的临床阶段生物技术公司VielaBio，Inc.的首席执行官，并自2019年1月起担任其董事会主席。2010年10月至2018年2月，姚博士在MedImmune担任多个领导职位，最近担任呼吸，炎症，自身免疫IMED高级副总裁，负责人。姚博士还担任阿斯利康公司免疫肿瘤专营权的高级副总裁，负责人。在MedImmune和AstraZeneca任职之前，姚博士曾担任Genentech免疫学，传染病，神经科学和代谢疾病PTL主管。此前，姚博士是Tanox，Inc.的Vice President和研究主管，该公司于2007年被Genentech收购。姚博士是VielaBio，Inc.和Immune-ONC Therapeutics，Inc.（一家开发癌症生物疗法的私营生物技术公司）的董事。姚博士在中国安徽安徽医科大学获得免疫学硕士学位，并在爱荷华大学获得微生物学和免疫学博士学位。
- Zhengbin Yao has served as a member of the Board since June 2021. From May 2021 to the present, Dr. Yao served as the Chief Executive Officer and chairman of the board of directors of ArriVent Biopharma, a biotechnology company. From March 2018 to March 2021, Dr. Yao served as the Chief Executive Officer, President, and from January 2019 to March 2021 also as chairman of the board of directors of Viela Bio, Inc., a biotechnology company, until it was acquired by Horizon Therapeutics in March 2021. From October 2010 to February 2018, Dr. Yao served as Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED at MedImmune, the biologics division of AstraZeneca plc and from October 2015 to February 2018 also as Senior Vice President, Head of Immuno Oncology Franchise. From March 2008 to September 2010, Dr. Yao served as Head of PTL for Immunology, Infectio Diseases, Neuroscience, and Metabolic Disease at Genentech, Inc., a biopharmaceutical company. From October 2000 to September 2007, Dr. Yao held vario leadership roles at Tanox Inc., a biopharmaceutical company, and was Vice President and Head of Research before it was acquired by Genentech, Inc. in 2007. Dr. Yao currently serves on the board of directors of Visen Pharmaceuticals, a biopharmaceutical company, and Nikang Therapeutics, Inc., a biotechnology company.
- Yanling Cao
-
Yanling Cao自2018年2月以来一直担任我们的董事会成员。曹先生是博裕资本（Boyu Capital）的创始成员和合伙人，自2011年3月起负责梦百合领域的投资和投资组合管理。任职Boyu公司之前，他曾担任General Atlantic公司（从2007年12月到2011年1月）、Goldman Sachs公司（从2006年7月到2007年11月）的投资专业人员，在那里他曾从事多种战略和金融交易。曹先生自2016年5月起担任生物制剂合同开发和制造公司Wuxi Biologics Cayman Inc.的董事。曹先生还在中国多家领先的制药、诊断和梦百合服务公司的董事会任职。曹先生在Middlebury College以优异成绩获得经济学和数学学士学位。
Yanling Cao has served as a member of our board of directors since February 2018. Mr. Cao is a founding member and Partner of Boyu Capital, or Boyu, and has been in charge of investments and portfolio management in the healthcare sector since March 2011. Prior to Boyu, Mr. Cao was an investment professional at General Atlantic from December 2007 to January 2011 and Goldman Sachs from July 2006 to November 2007 where he worked on a wide range of strategic and financial transactions. Mr. Cao has been a Director at WuXi Biologics Cayman Inc., a biologics contract development and manufacturing company, since May 2016. Mr. Cao also serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Mr. Cao received a B.A. in Economics and Mathematics, summa cum laude, from Middlebury College. - Yanling Cao自2018年2月以来一直担任我们的董事会成员。曹先生是博裕资本（Boyu Capital）的创始成员和合伙人，自2011年3月起负责梦百合领域的投资和投资组合管理。任职Boyu公司之前，他曾担任General Atlantic公司（从2007年12月到2011年1月）、Goldman Sachs公司（从2006年7月到2007年11月）的投资专业人员，在那里他曾从事多种战略和金融交易。曹先生自2016年5月起担任生物制剂合同开发和制造公司Wuxi Biologics Cayman Inc.的董事。曹先生还在中国多家领先的制药、诊断和梦百合服务公司的董事会任职。曹先生在Middlebury College以优异成绩获得经济学和数学学士学位。
- Yanling Cao has served as a member of our board of directors since February 2018. Mr. Cao is a founding member and Partner of Boyu Capital, or Boyu, and has been in charge of investments and portfolio management in the healthcare sector since March 2011. Prior to Boyu, Mr. Cao was an investment professional at General Atlantic from December 2007 to January 2011 and Goldman Sachs from July 2006 to November 2007 where he worked on a wide range of strategic and financial transactions. Mr. Cao has been a Director at WuXi Biologics Cayman Inc., a biologics contract development and manufacturing company, since May 2016. Mr. Cao also serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Mr. Cao received a B.A. in Economics and Mathematics, summa cum laude, from Middlebury College.
- Chris Nolet
-
Chris Nolet自2019年7月起担任公司董事。Nolet先生在审计服务行业和生命科学行业拥有超过40年的担任各种领导职务的经验。Nolet先生于2001年11月至2019年6月担任专业服务公司安永会计师事务所（Ernst&Young LLP&8220；ey&8221；）的审计合伙人。任职EY公司期间，他曾领导the West EY Life Sciences Industry Group，也曾任职California Life Sciences Industry Association的执行委员会和财务委员会（联席主席）。他也曾担任BIO公司（生物技术创新组织）的财务&投资委员会和新兴公司部门的成员。在加入EY之前，Nolet先生从1991年到2001年是普华永道会计师事务所（PricewaterhouseCoopers LLP）的合伙人。Nolet先生拥有圣地亚哥州立大学（San Diego State University）会计学B.S.学位，是加利福尼亚州的注册会计师（CPA-retired）。Nolet先生目前在VielaBio，Inc.、PolarityTE，Inc.和Ambrx Biopharma Inc.的董事会任职。
Chris Nolet has served as a director of our Company since July 2019. Mr. Nolet has more than 40 years of experience in various leadership roles in the audit services profession and in the life sciences industry. Mr. Nolet was an audit partner at Ernst & Young LLP “EY”, a professional services firm, from November 2001 to June 2019. While at EY, he led the West EY Life Sciences Industry Group and served on both the Executive Committee and Finance Committee (Co-Chair) of the California Life Sciences Industry Association. He was also a member of the Finance & Investment Committee and Emerging Companies Section of BIO (the Biotechnology Innovation Organization). Prior to EY, Mr. Nolet was a partner at PricewaterhouseCoopers LLP from 1991 to 2001. Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant (CPA - Retired) in California. Mr. Nolet currently serves on the board of directors of Viela Bio, Inc., PolarityTE, Inc. and Ambrx Biopharma Inc. - Chris Nolet自2019年7月起担任公司董事。Nolet先生在审计服务行业和生命科学行业拥有超过40年的担任各种领导职务的经验。Nolet先生于2001年11月至2019年6月担任专业服务公司安永会计师事务所（Ernst&Young LLP&8220；ey&8221；）的审计合伙人。任职EY公司期间，他曾领导the West EY Life Sciences Industry Group，也曾任职California Life Sciences Industry Association的执行委员会和财务委员会（联席主席）。他也曾担任BIO公司（生物技术创新组织）的财务&投资委员会和新兴公司部门的成员。在加入EY之前，Nolet先生从1991年到2001年是普华永道会计师事务所（PricewaterhouseCoopers LLP）的合伙人。Nolet先生拥有圣地亚哥州立大学（San Diego State University）会计学B.S.学位，是加利福尼亚州的注册会计师（CPA-retired）。Nolet先生目前在VielaBio，Inc.、PolarityTE，Inc.和Ambrx Biopharma Inc.的董事会任职。
- Chris Nolet has served as a director of our Company since July 2019. Mr. Nolet has more than 40 years of experience in various leadership roles in the audit services profession and in the life sciences industry. Mr. Nolet was an audit partner at Ernst & Young LLP “EY”, a professional services firm, from November 2001 to June 2019. While at EY, he led the West EY Life Sciences Industry Group and served on both the Executive Committee and Finance Committee (Co-Chair) of the California Life Sciences Industry Association. He was also a member of the Finance & Investment Committee and Emerging Companies Section of BIO (the Biotechnology Innovation Organization). Prior to EY, Mr. Nolet was a partner at PricewaterhouseCoopers LLP from 1991 to 2001. Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant (CPA - Retired) in California. Mr. Nolet currently serves on the board of directors of Viela Bio, Inc., PolarityTE, Inc. and Ambrx Biopharma Inc.
- Rachelle Jacques
-
Rachelle Jacques自2020年5月起担任我们的董事会成员。Jacques女士自2019年2月起担任Enzyvant Therapeutics，Inc.的首席执行官，该公司是住友大日本制药有限公司的全资子公司，专注于为罕见病患者开发疗法。此前，她于2017年开始担任亚力兄制药公司高级副总裁兼全球补充特许经营负责人，负责全球特许经营战略的制定和执行。从2016年到2017年，雅克女士担任Shire plc美国血液营销部的Vice President，该公司于2016年收购了Baxalta Inc.。在此之前，Jacques女士于2015年从百特国际有限公司（“；Baxter”；）剥离后，于2015年至2016年担任Baxalta业务运营Vice President。从2013年到2015年，雅克女士曾在百特公司担任领导职务，包括美国生物科学业务金融Vice President。加入Baxter之前，Jacques从1995年到2013年在Dow Corning Corporation担任多个职责递增的职位，包括美国和国际运营管理职位。Jacques女士在Corbus制药控股公司董事会任职Jacques女士在阿尔玛学院（Alma College）获得工商管理学士学位。
Rachelle Jacques has served as a director since June 2018. Dr. Jenkins is currently Managing Member of John K. Jenkins Advisors, LLC, an FDA foced strategic regulatory advisory firm located in Washington, DC. Previoly he served as Principal, Drug and Biological Products at Greenleaf Health from 2017 to 2023. In that role, he advised companies developing new drugs and seeking FDA approval. Dr. Jenkins also worked in vario positions of increasing responsibility at the FDA from May 1992 until his retirement in January 2017. During his tenure at the FDA, Dr. Jenkins served as Director of the Division of Pulmonary Drug Products from 1995 to 1999, Director of the Office of Drug Evaluation II from 1999 to 2002, and Director of the Office of New Drugs from 2002 to 2017. In his role as Director of the Office of New Drugs, Dr. Jenkins was responsible for oversight of all new drug reviewing divisions for small molecule drugs, therapeutic biologic proteins, and biosimilars. Dr. Jenkins was also a member of the Center for Drug Evaluation and Research Senior Leadership Team and represented the FDA during Congressional testimony on a variety of issues and during negotiations related to the renewal of the Prescription Drug er Fee Act. Prior to joining the FDA, Dr. Jenkins served as an Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV, and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, Virginia. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his post graduate medical training in internal medicine, pulmonary diseases, and critical care medicine at Virginia Commonalth University/Medical College of Virginia in Richmond. - Rachelle Jacques自2020年5月起担任我们的董事会成员。Jacques女士自2019年2月起担任Enzyvant Therapeutics，Inc.的首席执行官，该公司是住友大日本制药有限公司的全资子公司，专注于为罕见病患者开发疗法。此前，她于2017年开始担任亚力兄制药公司高级副总裁兼全球补充特许经营负责人，负责全球特许经营战略的制定和执行。从2016年到2017年，雅克女士担任Shire plc美国血液营销部的Vice President，该公司于2016年收购了Baxalta Inc.。在此之前，Jacques女士于2015年从百特国际有限公司（“；Baxter”；）剥离后，于2015年至2016年担任Baxalta业务运营Vice President。从2013年到2015年，雅克女士曾在百特公司担任领导职务，包括美国生物科学业务金融Vice President。加入Baxter之前，Jacques从1995年到2013年在Dow Corning Corporation担任多个职责递增的职位，包括美国和国际运营管理职位。Jacques女士在Corbus制药控股公司董事会任职Jacques女士在阿尔玛学院（Alma College）获得工商管理学士学位。
- Rachelle Jacques has served as a director since June 2018. Dr. Jenkins is currently Managing Member of John K. Jenkins Advisors, LLC, an FDA foced strategic regulatory advisory firm located in Washington, DC. Previoly he served as Principal, Drug and Biological Products at Greenleaf Health from 2017 to 2023. In that role, he advised companies developing new drugs and seeking FDA approval. Dr. Jenkins also worked in vario positions of increasing responsibility at the FDA from May 1992 until his retirement in January 2017. During his tenure at the FDA, Dr. Jenkins served as Director of the Division of Pulmonary Drug Products from 1995 to 1999, Director of the Office of Drug Evaluation II from 1999 to 2002, and Director of the Office of New Drugs from 2002 to 2017. In his role as Director of the Office of New Drugs, Dr. Jenkins was responsible for oversight of all new drug reviewing divisions for small molecule drugs, therapeutic biologic proteins, and biosimilars. Dr. Jenkins was also a member of the Center for Drug Evaluation and Research Senior Leadership Team and represented the FDA during Congressional testimony on a variety of issues and during negotiations related to the renewal of the Prescription Drug er Fee Act. Prior to joining the FDA, Dr. Jenkins served as an Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV, and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, Virginia. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his post graduate medical training in internal medicine, pulmonary diseases, and critical care medicine at Virginia Commonalth University/Medical College of Virginia in Richmond.
- Andreas Wicki
-
Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
Andreas Wicki has served on our board of directors since September 2017. Dr. Wicki has served as Chief Executive Officer of HBM Healthcare Investments AG formerly HBM BioVentures AG since July 2001. From 1998 to 2001 Dr. Wicki was the Senior Vice President of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki currently serves on the board of directors of Pacira BioSciences, Inc., a public pharmaceutical company, Buchler GmbH, HBM Healthcare Investments (Cayman) Ltd., HBM BioCapital Ltd., Viela Bio, Inc., a public clinical-stage biotechnology company, and Vitaeris, Inc., a private clinical-stage biopharmaceutical company. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry from the University of Bern, Switzerland. - Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
- Andreas Wicki has served on our board of directors since September 2017. Dr. Wicki has served as Chief Executive Officer of HBM Healthcare Investments AG formerly HBM BioVentures AG since July 2001. From 1998 to 2001 Dr. Wicki was the Senior Vice President of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki currently serves on the board of directors of Pacira BioSciences, Inc., a public pharmaceutical company, Buchler GmbH, HBM Healthcare Investments (Cayman) Ltd., HBM BioCapital Ltd., Viela Bio, Inc., a public clinical-stage biotechnology company, and Vitaeris, Inc., a private clinical-stage biopharmaceutical company. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry from the University of Bern, Switzerland.
- Pascal Soriot
-
Pascal Soriot于10月被任命为董事与首席执行官。从2010年到2012年9月，他担任罗氏制药公司（Roche AG）的制药部门的首席运营官。在这之前，他担任基因泰克（Genentech）的首席执行官，这是一家生物制剂公司，并领导了其与罗氏（Roche）的成功合并。他于1986年加入制药行业，并从那以后在全球多个大型公司担任高级管理职位。他在阿尔夫尔国立兽医学校（école Nationale Vétérinaire d’Alfort）获得兽医医学博士学位，在朱昂萨斯的高等商业学院（L’Institut Supérieur des Affaires）获得工商管理硕士学位。
Pascal Soriot has served as an Executive Director on the board of directors and Chief Executive Officer of AstraZeneca since October 2012. Prior to joining AstraZeneca, Mr. Soriot served as the Chief Operating Officer of Roche Pharma AG ("Roche") from January 2010 until Augt 2012. Prior to that, he served as the Chief Executive Officer of Genentech, Inc. from April 2009 to 2010, until its merger with Roche. In 2022, Mr. Soriot received a knighthood for services to life sciences and leadership in the global response to the COVID 19 pandemic. Mr. Soriot has also served as a director of Stainable Markets Initiative Limited since April 2023. - Pascal Soriot于10月被任命为董事与首席执行官。从2010年到2012年9月，他担任罗氏制药公司（Roche AG）的制药部门的首席运营官。在这之前，他担任基因泰克（Genentech）的首席执行官，这是一家生物制剂公司，并领导了其与罗氏（Roche）的成功合并。他于1986年加入制药行业，并从那以后在全球多个大型公司担任高级管理职位。他在阿尔夫尔国立兽医学校（école Nationale Vétérinaire d’Alfort）获得兽医医学博士学位，在朱昂萨斯的高等商业学院（L’Institut Supérieur des Affaires）获得工商管理硕士学位。
- Pascal Soriot has served as an Executive Director on the board of directors and Chief Executive Officer of AstraZeneca since October 2012. Prior to joining AstraZeneca, Mr. Soriot served as the Chief Operating Officer of Roche Pharma AG ("Roche") from January 2010 until Augt 2012. Prior to that, he served as the Chief Executive Officer of Genentech, Inc. from April 2009 to 2010, until its merger with Roche. In 2022, Mr. Soriot received a knighthood for services to life sciences and leadership in the global response to the COVID 19 pandemic. Mr. Soriot has also served as a director of Stainable Markets Initiative Limited since April 2023.
- 胡正国
-
胡正国（Edward Hu），1962年12月出生，硕士，美国国籍，已取得中华人民共和国外国人永久居留证。1983年-1985年，于杭州大学科学仪器厂任工程师；1988年-1989年，于中国大恒公司任经理；1989年-1990年，于德国Jurid Bremsbrag GmbH任工程师；1996年-1998年，担任美国默沙东高级财务分析师；1998年-2000年，担任美国Biogen Inc.商业策划经理；2000年-2007年，历任美国Tanox,Inc.财务总监，运营副总裁，高级副总裁及首席运营官；2007年-2017年，历任无锡药明康德新药开发有限公司（下称“药明有限”）常务副总裁及首席运营官，WuXiPharmaTech（Cayman）Inc.（下称“WuXiCayman（无锡开曼）”）常务副总裁及首席运营官、WuXiCayman（无锡开曼）首席运营官及首席财务官、药明有限首席财务官及首席投资官。胡正国先生同时担任WuXi Biologics（Cayman） Inc.（股票代码：2269.HK）非执行董事及其多家下属子公司的董事，2018年5月至今担任VielaBio,Inc（股票代码：VIE.NASDAQ）董事；亦担任New WuXi Life Science Investment Limited的董事及其多家下属子公司的董事。2017年3月至2019年1月担任无锡药明康德新药开发股份有限公司（下称“药明康德”）首席财务官、首席投资官，2018年8月至今担任药明康德联席首席执行官，2017年3月至今担任药明康德执行董事。
Edward Hu has served as a member of our board of directors since February 2018. Mr. Hu is the Co-Chief Executive Officer and director at WuXi AppTec Co., Ltd., or WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. Since August 2007 Mr. Hu has served in various executive management roles at WuXi AppTec, initially as Chief Operating Officer and then as Chief Financial Officer & Chief Investment Officer. In addition, Mr. Hu serves on the board of directors for WuXi Biologics Cayman, Inc., a biologics contract development and manufacturing organization listed on the Hong Kong Stock Exchange. Mr. Hu also serves on the boards of several private biopharmaceutical companies. Mr. Hu earned his B.S. in Physics from Zhejiang University, and his M.S. in Chemistry and MBA from Carnegie Mellon University. - 胡正国（Edward Hu），1962年12月出生，硕士，美国国籍，已取得中华人民共和国外国人永久居留证。1983年-1985年，于杭州大学科学仪器厂任工程师；1988年-1989年，于中国大恒公司任经理；1989年-1990年，于德国Jurid Bremsbrag GmbH任工程师；1996年-1998年，担任美国默沙东高级财务分析师；1998年-2000年，担任美国Biogen Inc.商业策划经理；2000年-2007年，历任美国Tanox,Inc.财务总监，运营副总裁，高级副总裁及首席运营官；2007年-2017年，历任无锡药明康德新药开发有限公司（下称“药明有限”）常务副总裁及首席运营官，WuXiPharmaTech（Cayman）Inc.（下称“WuXiCayman（无锡开曼）”）常务副总裁及首席运营官、WuXiCayman（无锡开曼）首席运营官及首席财务官、药明有限首席财务官及首席投资官。胡正国先生同时担任WuXi Biologics（Cayman） Inc.（股票代码：2269.HK）非执行董事及其多家下属子公司的董事，2018年5月至今担任VielaBio,Inc（股票代码：VIE.NASDAQ）董事；亦担任New WuXi Life Science Investment Limited的董事及其多家下属子公司的董事。2017年3月至2019年1月担任无锡药明康德新药开发股份有限公司（下称“药明康德”）首席财务官、首席投资官，2018年8月至今担任药明康德联席首席执行官，2017年3月至今担任药明康德执行董事。
- Edward Hu has served as a member of our board of directors since February 2018. Mr. Hu is the Co-Chief Executive Officer and director at WuXi AppTec Co., Ltd., or WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. Since August 2007 Mr. Hu has served in various executive management roles at WuXi AppTec, initially as Chief Operating Officer and then as Chief Financial Officer & Chief Investment Officer. In addition, Mr. Hu serves on the board of directors for WuXi Biologics Cayman, Inc., a biologics contract development and manufacturing organization listed on the Hong Kong Stock Exchange. Mr. Hu also serves on the boards of several private biopharmaceutical companies. Mr. Hu earned his B.S. in Physics from Zhejiang University, and his M.S. in Chemistry and MBA from Carnegie Mellon University.
高管简历
中英对照 | 中文 | 英文- Zhengbin Yao
Zhengbin Yao自2017年1月以来一直担任我们的董事会成员。姚博士自2018年2月起担任专注于自身免疫性和严重炎症性疾病的临床阶段生物技术公司VielaBio，Inc.的首席执行官，并自2019年1月起担任其董事会主席。2010年10月至2018年2月，姚博士在MedImmune担任多个领导职位，最近担任呼吸，炎症，自身免疫IMED高级副总裁，负责人。姚博士还担任阿斯利康公司免疫肿瘤专营权的高级副总裁，负责人。在MedImmune和AstraZeneca任职之前，姚博士曾担任Genentech免疫学，传染病，神经科学和代谢疾病PTL主管。此前，姚博士是Tanox，Inc.的Vice President和研究主管，该公司于2007年被Genentech收购。姚博士是VielaBio，Inc.和Immune-ONC Therapeutics，Inc.（一家开发癌症生物疗法的私营生物技术公司）的董事。姚博士在中国安徽安徽医科大学获得免疫学硕士学位，并在爱荷华大学获得微生物学和免疫学博士学位。
Zhengbin Yao has served as a member of the Board since June 2021. From May 2021 to the present, Dr. Yao served as the Chief Executive Officer and chairman of the board of directors of ArriVent Biopharma, a biotechnology company. From March 2018 to March 2021, Dr. Yao served as the Chief Executive Officer, President, and from January 2019 to March 2021 also as chairman of the board of directors of Viela Bio, Inc., a biotechnology company, until it was acquired by Horizon Therapeutics in March 2021. From October 2010 to February 2018, Dr. Yao served as Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED at MedImmune, the biologics division of AstraZeneca plc and from October 2015 to February 2018 also as Senior Vice President, Head of Immuno Oncology Franchise. From March 2008 to September 2010, Dr. Yao served as Head of PTL for Immunology, Infectio Diseases, Neuroscience, and Metabolic Disease at Genentech, Inc., a biopharmaceutical company. From October 2000 to September 2007, Dr. Yao held vario leadership roles at Tanox Inc., a biopharmaceutical company, and was Vice President and Head of Research before it was acquired by Genentech, Inc. in 2007. Dr. Yao currently serves on the board of directors of Visen Pharmaceuticals, a biopharmaceutical company, and Nikang Therapeutics, Inc., a biotechnology company.- Zhengbin Yao自2017年1月以来一直担任我们的董事会成员。姚博士自2018年2月起担任专注于自身免疫性和严重炎症性疾病的临床阶段生物技术公司VielaBio，Inc.的首席执行官，并自2019年1月起担任其董事会主席。2010年10月至2018年2月，姚博士在MedImmune担任多个领导职位，最近担任呼吸，炎症，自身免疫IMED高级副总裁，负责人。姚博士还担任阿斯利康公司免疫肿瘤专营权的高级副总裁，负责人。在MedImmune和AstraZeneca任职之前，姚博士曾担任Genentech免疫学，传染病，神经科学和代谢疾病PTL主管。此前，姚博士是Tanox，Inc.的Vice President和研究主管，该公司于2007年被Genentech收购。姚博士是VielaBio，Inc.和Immune-ONC Therapeutics，Inc.（一家开发癌症生物疗法的私营生物技术公司）的董事。姚博士在中国安徽安徽医科大学获得免疫学硕士学位，并在爱荷华大学获得微生物学和免疫学博士学位。
- Zhengbin Yao has served as a member of the Board since June 2021. From May 2021 to the present, Dr. Yao served as the Chief Executive Officer and chairman of the board of directors of ArriVent Biopharma, a biotechnology company. From March 2018 to March 2021, Dr. Yao served as the Chief Executive Officer, President, and from January 2019 to March 2021 also as chairman of the board of directors of Viela Bio, Inc., a biotechnology company, until it was acquired by Horizon Therapeutics in March 2021. From October 2010 to February 2018, Dr. Yao served as Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED at MedImmune, the biologics division of AstraZeneca plc and from October 2015 to February 2018 also as Senior Vice President, Head of Immuno Oncology Franchise. From March 2008 to September 2010, Dr. Yao served as Head of PTL for Immunology, Infectio Diseases, Neuroscience, and Metabolic Disease at Genentech, Inc., a biopharmaceutical company. From October 2000 to September 2007, Dr. Yao held vario leadership roles at Tanox Inc., a biopharmaceutical company, and was Vice President and Head of Research before it was acquired by Genentech, Inc. in 2007. Dr. Yao currently serves on the board of directors of Visen Pharmaceuticals, a biopharmaceutical company, and Nikang Therapeutics, Inc., a biotechnology company.
- Jorn Drappa
Jorn Drappa自2018年2月起担任我们的首席医疗官兼研究与开发负责人。在加入我们之前，Drapa博士自2011年3月以来在MedImmune（我们最大的股东阿斯利康公司的生物制剂部门）担任各种职责递增的职务，最近的职务是临床开发Vice President，在那里他领导呼吸、炎症、自身免疫、心血管、代谢疾病和传染病的临床职能。此前，Drapa博士曾担任Genentech炎症和自身免疫资产的高级医疗总监。Drapa博士在德国科隆大学（University of Cologne）获得医学学位，以及医学博士学位。他在Cornell Medical School/Hospital for Special Surgery进行研究生学习，随后在New York Hospital住院医师和Hospital for Special Surgery风湿病学奖学金。
Jorn Drappa has served as our Chief Medical Officer since September 2021. Prior to joining Ventyx, Dr. Drappa served as Executive Vice President, Research and Development for Horizon Therapeutics plc from March 2021 to September 2021 and as Head of Research & Development and Chief Medical Officer at Viela Bio, Inc., from February 2018 until its acquisition by Horizon in March 2021. Prior to Viela, Dr. Drappa served as Vice President, Clinical Biologics at MedImmune from May 2011 to February 2018. From March 2006 through May 2011 Dr. Drappa also served in increasingly senior roles at Genentech, including as Senior Medical Director from August 2008 to May 2011. Prior to Genentech, Dr. Drappa served as Associate Medical Director at Amgen from March 2003 to March 2006. Earlier in his career, Dr. Drappa served as a physician at the Hospital for Specialty Surgery in New York. Dr. Drappa received his M.D. and Ph.D. in Medicine from the University of Cologne in 1991 and completed postdoctoral studies in immunology at Cornell University from 1993 to 1996.- Jorn Drappa自2018年2月起担任我们的首席医疗官兼研究与开发负责人。在加入我们之前，Drapa博士自2011年3月以来在MedImmune（我们最大的股东阿斯利康公司的生物制剂部门）担任各种职责递增的职务，最近的职务是临床开发Vice President，在那里他领导呼吸、炎症、自身免疫、心血管、代谢疾病和传染病的临床职能。此前，Drapa博士曾担任Genentech炎症和自身免疫资产的高级医疗总监。Drapa博士在德国科隆大学（University of Cologne）获得医学学位，以及医学博士学位。他在Cornell Medical School/Hospital for Special Surgery进行研究生学习，随后在New York Hospital住院医师和Hospital for Special Surgery风湿病学奖学金。
- Jorn Drappa has served as our Chief Medical Officer since September 2021. Prior to joining Ventyx, Dr. Drappa served as Executive Vice President, Research and Development for Horizon Therapeutics plc from March 2021 to September 2021 and as Head of Research & Development and Chief Medical Officer at Viela Bio, Inc., from February 2018 until its acquisition by Horizon in March 2021. Prior to Viela, Dr. Drappa served as Vice President, Clinical Biologics at MedImmune from May 2011 to February 2018. From March 2006 through May 2011 Dr. Drappa also served in increasingly senior roles at Genentech, including as Senior Medical Director from August 2008 to May 2011. Prior to Genentech, Dr. Drappa served as Associate Medical Director at Amgen from March 2003 to March 2006. Earlier in his career, Dr. Drappa served as a physician at the Hospital for Specialty Surgery in New York. Dr. Drappa received his M.D. and Ph.D. in Medicine from the University of Cologne in 1991 and completed postdoctoral studies in immunology at Cornell University from 1993 to 1996.
- Aaron Ren
Aaron Ren自2018年2月起担任我们的Vice President，业务开发和运营主管，管理业务开发，质量，信息技术，采购和合同职能。在加入我们之前，任博士于2016年3月至2018年2月在MedImmune任职，担任生物制药发展集团董事和MedImmune China Lead，管理公司在中国的研究与开发计划。2014年2月至2016年2月，任博士曾担任MedImmune&8217；s Partnering and Strategy Group的副董事，并领导多个业务开发交易。在加入MedImmune之前，任博士于2011年9月至2014年1月担任麦肯锡公司（McKinsey and Company）的管理顾问。他也曾担任SR One公司、Schering-Plough公司、Abbott Labs公司的多种职务，并承担越来越大的责任，在那里他曾担任Humira公司的高级临床药理学家，在那里他开始了他的职业生涯。任博士在中国北京大学获得细胞生物学和遗传学学士学位，在宾夕法尼亚大学沃顿商学院获得金融和梦百合管理荣誉工商管理硕士学位，并在华盛顿大学获得药剂学博士学位，期间他是礼来公司的研究员。
Aaron Ren has served as our Vice President, Head of Business Development and Operations since February 2018 managing business development, quality, information technology, procurement and contracts functions. Prior to joining us, from March 2016 to February 2018 Dr. Ren was with MedImmune, as a Director within BioPharmaceutical Development group and as MedImmune China Lead, managing the company’s research and development initiatives for China. From February 2014 to February 2016 Dr. Ren was an Associate Director within MedImmune’s Partnering and Strategy group and led multiple business development transactions. Before joining MedImmune, Dr. Ren was a management consultant with McKinsey and Company from September 2011 to January 2014. Dr. Ren also held various roles with increasing responsibilities respectively with SR One, Schering-Plough, and Abbott Labs, where he started his career as a senior clinical pharmacologist for Humira. Dr. Ren received his B.S. in Cell Biology and Genetics from Peking University in China, M.B.A. with honors in Finance and Healthcare Management from the Wharton School at the University of Pennsylvania and a Ph.D. in Pharmaceutics from the University of Washington, during which he was an Eli Lilly Fellow.- Aaron Ren自2018年2月起担任我们的Vice President，业务开发和运营主管，管理业务开发，质量，信息技术，采购和合同职能。在加入我们之前，任博士于2016年3月至2018年2月在MedImmune任职，担任生物制药发展集团董事和MedImmune China Lead，管理公司在中国的研究与开发计划。2014年2月至2016年2月，任博士曾担任MedImmune&8217；s Partnering and Strategy Group的副董事，并领导多个业务开发交易。在加入MedImmune之前，任博士于2011年9月至2014年1月担任麦肯锡公司（McKinsey and Company）的管理顾问。他也曾担任SR One公司、Schering-Plough公司、Abbott Labs公司的多种职务，并承担越来越大的责任，在那里他曾担任Humira公司的高级临床药理学家，在那里他开始了他的职业生涯。任博士在中国北京大学获得细胞生物学和遗传学学士学位，在宾夕法尼亚大学沃顿商学院获得金融和梦百合管理荣誉工商管理硕士学位，并在华盛顿大学获得药剂学博士学位，期间他是礼来公司的研究员。
- Aaron Ren has served as our Vice President, Head of Business Development and Operations since February 2018 managing business development, quality, information technology, procurement and contracts functions. Prior to joining us, from March 2016 to February 2018 Dr. Ren was with MedImmune, as a Director within BioPharmaceutical Development group and as MedImmune China Lead, managing the company’s research and development initiatives for China. From February 2014 to February 2016 Dr. Ren was an Associate Director within MedImmune’s Partnering and Strategy group and led multiple business development transactions. Before joining MedImmune, Dr. Ren was a management consultant with McKinsey and Company from September 2011 to January 2014. Dr. Ren also held various roles with increasing responsibilities respectively with SR One, Schering-Plough, and Abbott Labs, where he started his career as a senior clinical pharmacologist for Humira. Dr. Ren received his B.S. in Cell Biology and Genetics from Peking University in China, M.B.A. with honors in Finance and Healthcare Management from the Wharton School at the University of Pennsylvania and a Ph.D. in Pharmaceutics from the University of Washington, during which he was an Eli Lilly Fellow.
- Mitchell Chan
Mitchell Chan自2019年6月起担任我们的首席财务官。陈先生于2018年9月加入我们，担任我们的Vice President，财务和公司战略主管。陈先生负责领导我们的企业融资，财务运营，会计，税务，金库，投资者关系，公共关系和发展企业战略。自2015年9月至2018年8月，陈先生担任北美阿斯利康投资者关系总监。任职AstraZeneca公司之前，Chan先生曾担任Genentech-Roche公司的多种职务（从2010年6月到2015年8月），最近担任高级副总裁。财务经理。Chan先生获得斯坦福大学（Stanford University），加州大学哈斯分校（University of California Haas）和宾夕法尼亚大学（Wharton）的执行认证，并获得多伦多大学（University of Toronto）的B.S.，M.S.和M.B.A.（罗特曼管理学院）。
Mitchell Chan has served on Board since December of 2021. Mr. Chan has served as the Chief Financial Officer of REGENXBIO (Nasdaq: RGNX) since September 2024. Mr. Chan previoly served as the Chief Financial Officer and Chief Biness Officer at ABio X Holdings, Inc., a healthcare dedicated incubator, from May 2023 to October 2023. From January 2022 to April 2023, Mr. Chan served as an Operating Partner at Catalio Capital Management, LP, a venture capital fund foced on investments in biomedical technology companies. From September 2018 to June 2022, Mr. Chan was at Viela Bio, Inc. (previoly, Nasdaq: VIE), a clinical stage biotechnology company, and in his last role served as the Chief Financial Officer and oversaw the acquisition of Viela by Horizon Therapeutics plc. Prior to Viela, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America (Nasdaq: AZN), a multinational pharmaceutical and biotechnology company. Mr. Chan also held several roles of increasing responsibility within the Roche Group, at Genetech, Inc. and F. Hoffmann La Roche AG, including in biooncology commercial finance, research and development finance, and mergers and acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his B.S. in Biochemistry, M.S. in Medial Biophysics, and MBA from the University of Toronto (Rotman School of Management).- Mitchell Chan自2019年6月起担任我们的首席财务官。陈先生于2018年9月加入我们，担任我们的Vice President，财务和公司战略主管。陈先生负责领导我们的企业融资，财务运营，会计，税务，金库，投资者关系，公共关系和发展企业战略。自2015年9月至2018年8月，陈先生担任北美阿斯利康投资者关系总监。任职AstraZeneca公司之前，Chan先生曾担任Genentech-Roche公司的多种职务（从2010年6月到2015年8月），最近担任高级副总裁。财务经理。Chan先生获得斯坦福大学（Stanford University），加州大学哈斯分校（University of California Haas）和宾夕法尼亚大学（Wharton）的执行认证，并获得多伦多大学（University of Toronto）的B.S.，M.S.和M.B.A.（罗特曼管理学院）。
- Mitchell Chan has served on Board since December of 2021. Mr. Chan has served as the Chief Financial Officer of REGENXBIO (Nasdaq: RGNX) since September 2024. Mr. Chan previoly served as the Chief Financial Officer and Chief Biness Officer at ABio X Holdings, Inc., a healthcare dedicated incubator, from May 2023 to October 2023. From January 2022 to April 2023, Mr. Chan served as an Operating Partner at Catalio Capital Management, LP, a venture capital fund foced on investments in biomedical technology companies. From September 2018 to June 2022, Mr. Chan was at Viela Bio, Inc. (previoly, Nasdaq: VIE), a clinical stage biotechnology company, and in his last role served as the Chief Financial Officer and oversaw the acquisition of Viela by Horizon Therapeutics plc. Prior to Viela, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America (Nasdaq: AZN), a multinational pharmaceutical and biotechnology company. Mr. Chan also held several roles of increasing responsibility within the Roche Group, at Genetech, Inc. and F. Hoffmann La Roche AG, including in biooncology commercial finance, research and development finance, and mergers and acquisitions. Mr. Chan is the recipient of Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton) and earned his B.S. in Biochemistry, M.S. in Medial Biophysics, and MBA from the University of Toronto (Rotman School of Management).
- William Ragatz
William Ragatz自2019年1月起担任我们的Vice President兼商业主管。从2017年2月至2019年1月，Ragatz先生担任我们最大股东阿斯利康（AstraZeneca）的营销总监，领导Anifrolumab在系统性红斑狼疮中的全球商业战略。在加入AstraZeneca之前，Ragatz先生在Boehringer-Ingelheim工作了15年，这是一家C.H.Boehringer Sohn AG&Ko的集团。KG，职责不断增加，最近担任营销总监，此前曾担任运营总监。Ragatz先生在爱荷华州立大学（Iowa State University）获得会计学学士学位，并在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位。
William Ragatz has served as our Vice President, Head of Commercial since January 2019. From February 2017 to January 2019 Mr. Ragatz served as a Director of Marketing for AstraZeneca, our largest stockholder, leading the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Prior to joining AstraZeneca, Mr. Ragatz spent 15 years at Boehringer-Ingelheim, a group of C.H. Boehringer Sohn AG & Ko. KG, in roles of increasing responsibility, most recently as Director of Marketing and previously as Director of Operations. Mr. Ragatz received his B.B.A. in Accounting from Iowa State University and M.B.A. from the Fuqua School of Business at Duke University.- William Ragatz自2019年1月起担任我们的Vice President兼商业主管。从2017年2月至2019年1月，Ragatz先生担任我们最大股东阿斯利康（AstraZeneca）的营销总监，领导Anifrolumab在系统性红斑狼疮中的全球商业战略。在加入AstraZeneca之前，Ragatz先生在Boehringer-Ingelheim工作了15年，这是一家C.H.Boehringer Sohn AG&Ko的集团。KG，职责不断增加，最近担任营销总监，此前曾担任运营总监。Ragatz先生在爱荷华州立大学（Iowa State University）获得会计学学士学位，并在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位。
- William Ragatz has served as our Vice President, Head of Commercial since January 2019. From February 2017 to January 2019 Mr. Ragatz served as a Director of Marketing for AstraZeneca, our largest stockholder, leading the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Prior to joining AstraZeneca, Mr. Ragatz spent 15 years at Boehringer-Ingelheim, a group of C.H. Boehringer Sohn AG & Ko. KG, in roles of increasing responsibility, most recently as Director of Marketing and previously as Director of Operations. Mr. Ragatz received his B.B.A. in Accounting from Iowa State University and M.B.A. from the Fuqua School of Business at Duke University.
- Jim Kastenmayer
Jim Kastenmayer自2020年1月起担任我们的总法律顾问，管理法律和合规风险，并担任公司秘书。在加入我们之前，Kastenmayer先生于2017年9月至2019年12月在阿斯利康（AstraZeneca）担任全球法律总监，为美国肿瘤商业业务提供战略法律建议并管理合同诉讼。从2012年5月至2017年9月，Kastenmayer先生担任阿斯利康（AstraZeneca）的高级专利总监，负责心血管和代谢疾病的大分子和小分子计划和产品的全球IP战略。Kastenmayer先生是一名注册专利律师，在密歇根州立大学（Michigan State University）获得生物化学与细胞与分子生物学博士学位，在乔治城大学法律中心（Georgetown University Law Center）获得法学博士学位。
Jim Kastenmayer has served as our General Counsel since January 2020 managing legal and compliance risks and serving as corporate secretary. Before joining us, from September 2017 to December 2019 Mr. Kastenmayer served as Global Legal Director with AstraZeneca, providing strategic legal advice to the US Oncology commercial business and managing contract litigation. From May 2012 to September 2017 Mr. Kastenmayer was a Senior Patent Director with AstraZeneca, responsible for the global IP strategy for large and small molecule programs and products for cardiovascular and metabolic diseases. Mr. Kastenmayer is a registered patent attorney and received his Ph.D. in Biochemistry and Cell & Molecular Biology from Michigan State University and his J.D. from Georgetown University Law Center.- Jim Kastenmayer自2020年1月起担任我们的总法律顾问，管理法律和合规风险，并担任公司秘书。在加入我们之前，Kastenmayer先生于2017年9月至2019年12月在阿斯利康（AstraZeneca）担任全球法律总监，为美国肿瘤商业业务提供战略法律建议并管理合同诉讼。从2012年5月至2017年9月，Kastenmayer先生担任阿斯利康（AstraZeneca）的高级专利总监，负责心血管和代谢疾病的大分子和小分子计划和产品的全球IP战略。Kastenmayer先生是一名注册专利律师，在密歇根州立大学（Michigan State University）获得生物化学与细胞与分子生物学博士学位，在乔治城大学法律中心（Georgetown University Law Center）获得法学博士学位。
- Jim Kastenmayer has served as our General Counsel since January 2020 managing legal and compliance risks and serving as corporate secretary. Before joining us, from September 2017 to December 2019 Mr. Kastenmayer served as Global Legal Director with AstraZeneca, providing strategic legal advice to the US Oncology commercial business and managing contract litigation. From May 2012 to September 2017 Mr. Kastenmayer was a Senior Patent Director with AstraZeneca, responsible for the global IP strategy for large and small molecule programs and products for cardiovascular and metabolic diseases. Mr. Kastenmayer is a registered patent attorney and received his Ph.D. in Biochemistry and Cell & Molecular Biology from Michigan State University and his J.D. from Georgetown University Law Center.